Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 4 of 5

“It’s a bit like the chimera, from the Greek tradition, part one animal part another animal — it’s part T-cell receptor and part antibody,” says Renier Brentjens, director of cellular therapeutics at Memorial Sloan Kettering

Renier Brentjens, director of cellular therapeutics at Memorial Sloan Kettering Cancer Center, started working on CAR-T cells in 1999

Source  Courtesy of Renier Brentjens